Tarsus Pharmaceuticals Inc

TARS has erupted to new highs after breaking out of a prolonged consolidation on strong institutional volume, with moving averages aligned and heavy options bullishness; however, extreme overbought readings and steep extension above key EMAs warrant deferring fresh entries until a shallow pullback into the broken-resistance zone near $79–$80 or into the rising 9/20 EMAs for optimal execution alignment.

• ↑Xtemvi Q2 product sales hit $173.9M, up 69% YoY.
• ↑Full-year Xtemvi guidance boosted to $685M on expected Q4 patient growth.
• ↓Adjusted loss widened to $0.43 per share, highlighting profitability risk.